Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Novartis Japan Revenue Nearly Hit Bottom, FY2016 Sales Down 3.7%: New Chief
Japan sales of Novartis appear to have nearly touched bottom in FY2016 as its major products with no generic competition grew year on year across the board, but the company still has a long way to go before staging a…
To read the full story
Related Article
- Novartis Wants to Deliver CAR-T Therapy to Japanese Patients ASAP: Exec
July 25, 2017
- Ex-Lilly Exec Tsunaba Tapped as Novartis Japan Chief
February 7, 2017
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 25, 2026
- EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
June 25, 2026
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…